AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06726044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitaion after ACL reconstruction plus inertial exercises
Description: The SR+I group, consisting of 12 participants, underwent a standard rehabilitation program twice a week for 12 weeks including inertial exercises. Each session lasted approximately 70 minutes and was conducted by the same therapist.~Subjects also performed inertial exercises from the fifth week of rehabilitation. These exercises were conducted on an InerKnee. The inertial exercises protocol included: knee extension exercises performed in a seated position for the operated leg, 4 sets of exercises, each lasting 15 seconds individually, adjusted resistance to maintain a 1-second extension cycle, passive rest periods of 2 minutes between sets After 12 weeks of rehabilitation, effectiveness was evaluated using standard tests the same as in SR group.
Study NCT05125432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Description: Acupuncture group Patients with breast cancer who experienced AIA were assessed by the Brief Pain Inventory (BPI)scale and McMasters College Osteoarthritis Index Score (WOMAC). Patients who met the criteria for inclusion would receive regular acupuncture treatment. The location of acupuncture is based on the principles of acupuncture treatment in Traditional Chinese medicine. Patients with high scores and obvious pain received standardized acupuncture treatment, and standard acupuncture points and most painful joint (up to 3) specific point. Meanwhile, blood samples of patients were collected, and SNP related to AIA was screened through SNP typing technology.
Study NCT05466253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fixed Orthodontic treatment
Description: All the patients will receive the indicated periodontal surgical treatment. and the patients will then be randomly divided into two groups - test group and control group Orthodontic treatment will be started in the test group (EARLY)10 days after periodontal surgery whereas the control group will receive orthodontic intervention (DELAYED) 3 months after periodontal surgery.
Study NCT06265805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive rehabilitation therapy
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06265805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive rehabilitation therapy
Description: Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study NCT06265805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The observation group was given enteral nutritional support with Intermittent Oro-esophageal Tube according to the following procedure: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06265805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient\&#39;s cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study NCT05578976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV Infusion
Study NCT06163638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GRANDPACT Project
Description: To investigate whether grandparents and grandchildren are more co-physically active, have a better cognitive and physical function, psychosocial well-being, quality of the family relationship due to the intervention, we compare the intervention phase (B) with a pre phase (A), a in between period (A) and another intervention period (B)
Study NCT05600322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate Hydrochloride
Description: Enrolled patients will be instilled with 50 mL hexaminolevulinate hydrochloride as intravesical solution (Hexvix) in the bladder for one hour at Visit 2. After bladder evacuation, the cystoscopic examinations will be performed in both white and blue light.
Study NCT05600322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Richard Wolf Photodynamic Diagnostic Equipment (PDD) system
Description: Cystoscopy in White and Blue light will be done using the Richard Wolf PDD system.
Study NCT06146374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for SLV213
Description: Microcrystalline cellulose in a size 1 orange hard gelatin capsule.
Study NCT05742750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Apatinib Plus GP
Description: Patients received apatinib orally at 250 mg once a day irrespective of the patient weight.~Camrelizumab 200 mg was administered intravenously over 30 minutes every 3 weeks.~GP chemotherapy: Gemcitabine/Cisplatin (gemcitabine 1000mg/m2 + cisplatin 25mg/m2) will be administered on D1/D8 in every three weeks cycle and up to 8 cycles.~All patients continued combination treatment until disease progression, unacceptable toxicity, or discontinuation for any reason.
Study NCT06146374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV213
Description: SLV213 drug substance (K777) is 4-methylpiperazine-1-carboxylic acid, a vinyl sulfone cysteine protease inhibitor for the treatment of subjects infected with SARS-CoV-2. SLV213 is a white powder substance without excipients or stabilizer that will be packed into gelatin capsules which has been demonstrated to exhibit broad inhibitory properties against host cathepsins (e.g., Cathepsin L).
Study NCT05578976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV Infusion
Study NCT05578976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV Infusion
Study NCT05578976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral; Tablet
Study NCT06011070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gambling Personalised Feedback
Description: The intervention is a brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in gambling
Study NCT05539053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine A
Description: paclitaxel + N-Acetylcysteine orally short course
Study NCT06450145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon α-2b
Description: Eligible APL patients with arsenic-resistant relapse will enter the run-in period, and the subjects in the run-in phase will be treated with arsenic combined with venetoclax. After the run-in period, the patients were treated with interferon α-2b, arsenic trioxide for injection and venetoclax until the outcome of CR/PR/PD/ death/withdrawal/loss to follow-up occurred. Tumor assessments were performed every 4 to 6 weeks (as determined by the investigator) during trial treatment. Those who achieved CR/PR/PD/ withdrawal were then returned to standard treatment (treatment regimen was determined by the clinician), and those who completed the combination treatment period of the trial entered the survival follow-up period.
Study NCT06421337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BraiN20(R)
Description: SEP monitoring will be carried out using the BraiN20® medical device and appropriate electrodes. SEP of both median nerves will be recorded, transferred, and stored to the internal card for their evaluation. BraiN20® Medical Device provides an automatic reading of the presence and feature of a N20 response both ipsilateral and contralateral (as control) to the cerebral hemisphere affected by the stroke and do not require specific training. Furthermore, the device provides an outcome prediction (percentage of likelihood of having mRS ≤ 2 day 7 and 90 after stroke onset) based on an internal algorithm.~BraiN20® measures one N20 wave per 33 seconds. Scalp electrodes are easily embedded on a headband and the wrist electrodes on a glove.
Study NCT05295550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Realibility
Description: measurement of the thoracic kyphosis with flexicurve and Smartphone inclinometer app
Study NCT06468020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Gather.town gaming intervention
Description: The online game-based learning intervention (oGBL): The investigator will develop the oGBL intervention based on Rational Emotive Behavior Therapy (REBT), which consists of 5 sessions and plays a game through the Gather.Town platform.
Study NCT05711407 — intervention group
Intervention type: GENETIC
Intervention: Gene Polymorphisms of MMP-8
Description: Saliva Samples
Study NCT06724432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral melatonin
Description: Melatonin treated children receive a single dose of oral melatonin 0.5 mg/kg (for a max 10 mg) in a fixed volume of 5 mL of water , 1 hour before induction of anesthesia for surgery
Study NCT06724432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children in the Control group receive 5 ml of 5% dextrose solution once 1 hour before induction of anesthesia
Study NCT05431907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
Study NCT06726954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency real-time rTMS DLPF cortex protocol
Description: It was planned to apply the dorsolateral prefrontal cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
Study NCT06726954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency real-time rTMS M1 motor cortex protocol
Description: It was planned to apply the M1 motor cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
Study NCT06726954 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS Protocol
Description: It was planned to apply the daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
Study NCT06720961 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of surgical specimen
Description: Specimens of CD patients and non-IBD related patients will be collected during the surgery performed for clinical practice, without other risks for the patients, since we will use only leftover material after pathologist analysis. All of the collected surgical samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.
Study NCT06720961 — intervention group
Intervention type: PROCEDURE
Intervention: Collection of stool sample
Description: One week before the surgery to remove the stricture, fecal samples from CD patients belonging to B1, B2, B3 groups will be collected. They will be used for the exploratory objective. All of the collected fecal samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.
Study NCT06730958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum Follistatin-like protein 1
Description: Serum FSL1 level Test principle The kit uses a double-antibody sandwich enzyme-linked immunosorbent assay(ELISA) to assay the level ofHuman Follistatin Like Protein 1(FSTL1) in samples. Add Follistatin Like Protein 1(FSTL1)to monoclonal antibody.Enzyme well which is pre-coated with Human Follistatin Like Protein1(FSTL1)monoclonal antibody, incubation; then, add Follistatin Like Protein 1(FSTL1)antibodies labeled with biotin, and combined with Streptavidin-HRP to form immune complex; then carry out incubation and washing again to remove the uncombined enzyme. Then add Chromogen Solution A, B, the color of the liquid changes into the blue, And at the effect of acid, the color finally becomes yellow. The chroma of color and the concentration of the Human Substance Follistatin Like Protein 1(FSTL1) of sample were positively correlated.
Study NCT06728449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cumin tea
Description: The preparation involved boiling 200 ml of water with 2 grams of cumin seeds. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
Study NCT06728449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger Tea
Description: The preparation involved boiling 200 ml of water with 2 grams of ginger. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
Study NCT06728449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lemon Peel Tea
Description: The preparation involved boiling 200 ml of water with 2 grams of lemon peel. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
Study NCT06728449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional Tea
Description: The preparation involved boiling 200 ml of water with 2 grams of functional tisane (0.6 g cumin seeds, 0.6 g ginger, and 0.6 g lemon peel) Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.
Study NCT06728449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: A carbohydrate-controlled diet focuses on limiting refined carbohydrates and sugars and total carbohydrate restriction to 50-70gm per major meal.
Study NCT06740240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-Biotin
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI-Biotin. Tracer doses of 68Ga-FAPI-Biotin will be used to detect tumors by PET/CT
Study NCT06740240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-FAPI/18F-FDG
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
Study NCT05539053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine B
Description: paclitaxel +N Acetylcysteine orally long course
Study NCT05101707 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagus nerve stimulation
Description: Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
Study NCT05152095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccaria seed (Wang Bu Liu Xing) pre-attached to adhesive tape used for auricular acupressure
Description: Apply on auricular acupoints, Shenmen and Occiput, apply pressure for 3 minutes, 5 times per day, at the interval of 2 \~ 3 hours, for 5 days.
Study NCT05152095 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Plain ear adhesive tape
Description: Apply on Shenmen and Occiput without applying pressure for 5 days.
Study NCT04933058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: Pain management
Study NCT04933058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV fentanyl
Description: Pain management
Study NCT04946864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG2575 monotherapy
Study NCT04946864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: combination APG2575+pablociclib
Study NCT04784338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual shared medical visit
Description: a shared medical visit done by zoom in a group, 1.5 hours
Study NCT04784338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional classes
Description: A cooking class done by the teaching kitchen demonstrating cooking skills
Study NCT05101707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy
Description: Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
Study NCT05785338 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Posterior angle of the hard palate
Description: Fetal ultrasound
Study NCT04920994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: M-TAPA block
Description: A high-frequency linear ultrasound probe will be used, probe will be placed on the costochondral angle in the sagittal plane and angled deeply to view the lower aspect of the chondrium in the midline, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced into the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.
Study NCT04920994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCTAP block
Description: A high-frequency linear ultrasound probe will be placed obliquely on the upper abdominal wall, along the subcostal margin near the midline. After identifying the rectus abdominis muscle, the ultrasound probe will be gradually moved laterally along the subcostal margin until the transversus abdominis muscle will be identified lying posterior to the rectus muscle, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced medially and directed towards the transversus abdominis plane until its tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles on entering the neurofascial plane. The same procedure will be repeated on the contralateral side.
Study NCT04920994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20 ml 0.25% bupivacaine will be injected after the negative aspiration test.
Study NCT03939832 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen level
Description: A fraction of inspired oxygen level during cardiac surgery using cardiopulmonary bypass will be set differently: 0.5 versus 1.0.
Study NCT05735496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 injection
Description: TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.
Study NCT04921163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sodium aluminium phospate (SALP)
Description: 1 pancake daily for 4 days
Study NCT04921163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aluminium-free pancake
Description: 1 pancake daily for 4 days, without aluminium
Study NCT05646550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1 Infusion
Description: Short term (3h) infusion of CC-1
Study NCT04124367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: 30 ml once daily (+70 ml 0.9% saline)
Study NCT04124367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive brain stimulation
Description: 2 mA/35 cm² for 2x20 minutes, once daily
Study NCT04124367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml once daily 0.9% saline
Study NCT04124367 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham intervention
Description: 0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
Study NCT05702944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxybenzamine
Description: Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.